All Outputs (2)

Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission (2017)
Journal Article
Wild, S. H., Walker, J. J., Morling, J. R., McAllister, D. A., Colhoun, H., Farran, B., …Byrne, C. D. (2018). Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission. Diabetes Care, 41(2), https://doi.org/10.2337/dc17-1590

OBJECTIVE: To describe associations between alcoholic fatty liver disease (ALD) or non-alcoholic fatty liver disease (NAFLD) hospital admission and cardiovascular disease (CVD), cancer, and mortality in people with T2DM.
RESEARCH DESIGN AND METHODS:... Read More about Cardiovascular disease, cancer and mortality among people with type 2 diabetes and alcoholic or non-alcoholic fatty liver disease hospital admission.

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 (2017)
Journal Article
Gifford, F., Morling, J., & Fallowfield, J. (in press). Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Alimentary Pharmacology and Therapeutics, https://doi.org/10.1111/apt.13912

Background

Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a ver... Read More about Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.